<?xml version="1.0" encoding="UTF-8"?>
<p>Since 1976 when this virus was first identified, its infection has caused Ebola hemorrhagic fever (EHF) in humans with average fatality rates exceeding 50% (available online at 
 <ext-link ext-link-type="uri" xlink:href="https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease</ext-link>). The West African EBOV epidemic from 2014 to 2016 was the worst recorded EHF outbreak in history, resulting in 28,639 suspected and laboratory-confirmed cases and 11,316 deaths (available online at 
 <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/cost-of-ebola.html" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/cost-of-ebola.html</ext-link>). More recently, the Zaire Ebola outbreak in the Democratic Republic of Congo caused at least 139 deaths as of August 2018 (
 <xref rid="ref11" ref-type="bibr">11</xref>). Despite the high fatality rate, specific antiviral therapies are unavailable. Given the sporadic circulation of EBOV in Africa as well as the increased possibility of its international spread, it is imperative to develop prophylactic or therapeutic antivirals against EBOV infection (
 <xref rid="ref12" ref-type="bibr">12</xref>).
</p>
